InfuSystem Holdings, a provider of electronic infusion pumps and pain management services, delivered solid financial results for FY2025 with revenue growing 6.4% to $143.4 million. Operating income surged 73% and net income more than doubled, reflecting enhanced operational efficiency and favorable payer dynamics, including CMS’s recognition of select infusion pumps under the NOPAIN Act. Despite robust free cash flow supporting an aggressive $9.9 million share repurchase program, the company faces ongoing risks from regulatory shifts and liquidity constraints. Monitoring future reimbursement policies and capital deployment will be critical for assessing InfuSystem’s sustainability in a competitive healthcare equipment niche.